Are clinical parameters valuable prognostic factors in childhood primitive neuroectodermal tumors?A multivariate analysis of 105 cases

Radiotherapy and Oncology

Volumn 54, Issue 3, 2000, Pages 229-238

  Michiels, Erna M C ^a   Heikens, Janneke ^a   Jansen, Mieke J C E ^a   Oldenburger, Foppe ^a   Voûte, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Medulloblastoma; Primitive neuro ectodermal tumor; Prognostic factors

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDULLOBLASTOMA; MENINGIOMA; METASTASIS; MULTIVARIATE ANALYSIS; NETHERLANDS; NEUROECTODERM TUMOR; POSTERIOR FOSSA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MULTIVARIATE ANALYSIS; NEUROECTODERMAL TUMORS, PRIMITIVE; PROGNOSIS; SURVIVAL RATE;

EID: 0034161881     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00155-9     Document Type: Article

References (49)

1. Young J.L. Jr, Miller R.W. Incidence of malignant tumors in US children. J. Pediatr. 86:1975;254-258.
2. Schoenberg B.S., Schoenberg D.G., Christine B.W., et al. The epidemiology of primary intracranial neoplasms of childhood A population study. Mayo Clin. Proc. 51:1976;51-56.
3. Farwell J.R., Dohrmann G.J., Flannery J.T. Central nervous system tumors in children. Cancer. 40:1977;3123-3132.
4. Roberts R.O., Lynch C.F., Jones M.P., et al. Medulloblastoma: a population-based study of 532 cases. J. Neuropath. Exp. Neur. 50:1991;134-144.
5. Al-Mefty O., Jinkins J.R., el-Senoussi M., et al. Medulloblastomas: a review of modern management with a report on 75 cases. Surg. Neurol. 24:1985;606-624.
6. Weil M.D., Lamborn K., Edwards M.S., et al. Influence of a child's sex on medulloblastoma outcome. J. Am. Med. Assoc. 279:1998;1474-1476.
7. Bailey P., Cushing H. Medulloblastoma cerebelli A common type of midcerebellar glioma of childhood. Arch. Neurol. Neurosurg. Psychiatry. 14:1925;192-224.
8. Stevenson L., Echlin R. The nature and origin of some tumors of cerebellum (medulloblastoma). Arch. Neurol. Psychiatry. 31:1934;93-109.
9. Zimmerman H.M. Brain tumors: their incidence and classification in man and their experimental production. Ann. N. Y. Acad. Sci. 159:1969;337-359.
10. Zu Rhein G.M., Varakis J.N. Perinatal induction of medulloblastomas in Syrian golden hamsters by a human polyoma virus (JC). Natl. Cancer Inst. Monogr. 51:1979;205-208.
11. Nagashima K., Yasui K., Kimura J., et al. Induction of brain tumors by a newly isolated JC virus (Tokyo-1 strain). Am. J. Pathol. 116:1984;455-463.
12. Yokota N., Aruga J., Takai S., et al. Predominant expression of human zic in cerebellar granule cell lineage and medulloblastoma. Cancer Res. 56:1996;377-383.
13. Duffner P.K., Cohen M.E., Myers M.H., et al. Survival of children with brain tumors: SEER Program 1973-1980. Neurology. 36:1986;597-601.
14. Tait D.M., Thornton-Jones H., Bloom H.J., et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur. J. Cancer. 26:1990;464-469.
15. Evans A.E., Jenkin R.D.T., Sposto R., et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J. Neurosurg. 72:1990;572-582.
16. Packer R.J., Sutton L.N., Goldwein J.W., et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J. Neurosurg. 74:1991;433-440.
17. Novakovic B. US childhood cancer survival 1973-1987. Med. Pediatr. Oncol. 23:1994;480-486.
18. Kopelson G., Linggood R.M., Kleinman G.M. Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management Cancer. 51:1983;312-319.
19. Zerbini C., Gelber R.D., Weinberg D., et al. Prognostic factors in medulloblastoma, including DNA ploidy. J. Clin. Oncol. 11:1993;616-622.
20. Tait D.M., Eeles R.A., Carter R., et al. Ploidy and proliferative index in medulloblastoma: useful prognostic factors? Eur. J. Cancer. 29A:1993;1383-1387.
21. Carrie C., Lasset C., Alapetite C., et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma Retrospective study of 156 patients. Cancer. 74:1994;2352-2360.
22. Cervoni L., Cantore G. Medulloblastoma in pediatric age: a single-institution review of prognostic factors. Child Nerv. Syst. 11:1995;80-85.
23. Gilbertson R.J., Pearson A.D., Perry R.H., et al. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer. 71:1995;473-477.
24. Khafaga Y., Kandil A.E., Jamshed A., et al. Treatment results for 149 medulloblastoma patients from one institution. Int. J. Radiat. Oncol. Biol. Phys. 35:1996;501-506.
25. Pezzotta S., Cordero di Montezemolo L., Knerich R. et al. CNS-85 trial: a cooperative pediatric CNS tumor study-results of treatment of medulloblastoma patients. Child Nerv. Syst. 12:1996;87-96.
26. Sobel E.L., Gilles F.H., Leviton A., et al. Survival of children with infratentorial neuroglial tumors The Childhood Brain Tumor Consortium. Neurosurgery. 39:1996;45-56.
27. Gilbertson R.J., Jaros E., Perry R.H., et al. Mitotic percentage index: a new prognostic factor for childhood medulloblastoma. Eur. J. Cancer. 33:1997;609-615.
28. Wang K.C., Lee J.I., Cho B.K., et al. Treatment outcome and prognostic factors of medulloblastoma. J. Korean Med. Sci. 9:1994;64-73.
29. David K.M., Casey A.T., Hayward R.D., et al. Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J. Neurosurg. 86:1997;13-21.
30. Tomita T., Yasue M., Engelhard H.H., et al. Flow cytometric DNA analysis of medulloblastoma Prognostic implication of aneuploidy. Cancer. 61:1988;744-749.
31. Yasue M., Tomita T., Engelhard H., et al. Prognostic importance of DNA ploidy in medulloblastoma of childhood. J. Neurosurg. 70:1989;385-391.
32. Bailey C.C., Gnekow A., Wellek S., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastomaInternational Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med. Pediatr. Oncol. 25:1995;166-178.
33. Grabenbauer G.G., Beck J.D., Erhardt J., et al. Postoperative radiotherapy of medulloblastoma Impact of radiation quality on treatment outcome. Am. J. Clin. Oncol. 19:1996;73-77.
34. Packer R.J., Sutton L.N., Elterman R., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin CCNU, and vincristine chemotherapy. J. Neurosurg. 81:1994;690-698.
35. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc. 3:1958;457-481.
36. Lee M., Wisoff J.H., Abbott R., et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting. Pediatr. Neurosurg. 20:1994;240-247.
37. Mahoney D.H. Jr, Strother D., Camitta B., et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. J. Clin. Oncol. 14:1996;382-388.
38. Finlay J.L., Goldman S., Wong M.C., et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group, J. Clin. Oncol. 14:1996;2495-2503.
39. Finlay J.L. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors. Bone Marrow Transplant. 18:(Suppl. 3):1996;S1-S5.
40. Graham M.L., Herndon J.E. II, Casey J.R., et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J. Clin. Oncol. 15:1997;1814-1823.
41. Dunkel I.J., Boyett J.M., Yates A., et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group, J. Clin. Oncol. 16:1998;222-228.
42. Gururangan S., Dunkel I.J., Goldman S., et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J. Clin. Oncol. 16:1998;2486-2493.
43. Caron H., van Sluis P., De Kraker J., et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma [see comments]. N. Engl. J. Med. 334:1996;225-230.
44. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med. Pediatr. Oncol. 24:1995;215-221.
45. Cogen P.H., Daneshvar L., Metzger A.K., et al. Deletion mapping of the medulloblastoma locus on chromosome 17p. Genomics. 8:1990;279-285.
46. Cogen P.H., Daneshvar L., Metzger A.K., et al. Involvement of multiple chromosome 17p loci in medulloblastoma tumorigenesis. Am. J. Hum. Genet. 50:1992;584-589.
47. Batra S.K., McLendon R.E., Koo J.S., et al. Prognostic implications of chromosome 17p deletions in human medulloblastomas. J. Neuro-Oncol. 24:1995;39-45.
48. Scheurlen W.G., Schwabe G.C., Joos S., et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J. Clin. Oncol. 16:1998;2478-2485.
49. Gilbertson R.J., Perry R.H., Kelly P.J., et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57:1997;3272-3280.